• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Opus Genetics Inc.

    4/23/26 6:11:57 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001145914
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Opus Genetics, Inc.
    SEC File Number
    001-34079
    Address of Issuer
    8 DAVIS DRIVE
    SUITE 220
    DURHAM
    NORTH CAROLINA
    27713
    Phone
    248-681-9815
    Name of Person for Whose Account the Securities are To Be Sold
    SCHACHLE JOSEPH K
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Raymond James & Associates
    880 Carillon Parkway
    St. Petersburg � FL � 33716
    469724519.287115000004/23/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/22/2026RSU GRANT VESISSUERCheckbox not checked1562504/23/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JOSEPH SCHACHLE
    4222 EMPEROR BLVD.
    STE. 470
    DURHAM � NC � 27703
    Common03/16/2026371919525.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/23/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Joseph Schachle

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRD

    DatePrice TargetRatingAnalyst
    3/30/2026$15.00Overweight
    Cantor Fitzgerald
    3/16/2026$10.00Outperform
    Oppenheimer
    1/20/2026$7.00Buy
    BTIG Research
    12/10/2025$9.00Buy
    B. Riley Securities
    11/25/2025$7.00Overweight
    Piper Sandler
    10/29/2025$8.00Outperform
    Wedbush
    10/16/2025$9.00Buy
    Chardan Capital Markets
    4/11/2025$6.00Buy
    Craig Hallum
    More analyst ratings

    $IRD
    SEC Filings

    View All

    SEC Form 144 filed by Opus Genetics Inc.

    144 - Opus Genetics, Inc. (0001228627) (Subject)

    4/23/26 6:11:57 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Opus Genetics Inc.

    144 - Opus Genetics, Inc. (0001228627) (Subject)

    4/23/26 5:55:19 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Opus Genetics Inc.

    EFFECT - Opus Genetics, Inc. (0001228627) (Filer)

    4/23/26 12:15:21 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

    RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026. The presentations will include data across key areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for presbyopia, and a post-hoc analysis of MIRA-2, a

    4/10/26 6:59:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

    - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year - - Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers - - Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (G

    4/6/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

    RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz

    3/24/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rodgers Richard J

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    4/22/26 4:32:27 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Manuso James S J

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    4/22/26 4:31:58 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Benton Susan

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    4/22/26 4:30:19 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Opus Genetics with a new price target

    Cantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00

    3/30/26 8:19:42 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Opus Genetics with a new price target

    Oppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00

    3/16/26 8:42:37 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Opus Genetics with a new price target

    BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00

    1/20/26 9:23:30 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/31/25 4:33:33 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Magrath George bought $97,600 worth of shares (100,000 units at $0.98), increasing direct ownership by 20% to 599,150 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/30/24 4:26:20 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Yerxa Benjamin R bought $9,834 worth of shares (10,000 units at $0.98), increasing direct ownership by 3% to 342,800 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    11/25/24 4:18:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Leadership Updates

    Live Leadership Updates

    View All

    Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial

    9/2/25 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Financials

    Live finance-specific insights

    View All

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive three-month data from the pediatric cohort

    9/30/25 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

    - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, In

    8/13/25 4:30:00 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Opus Genetics Inc.

    SC 13D - Opus Genetics, Inc. (0001228627) (Subject)

    10/29/24 5:26:27 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care